US2003013744A1PendingUtilityA1

3,4-diaryl thiophenes and analogs thereof having use as anti-inflammatory agents

Assignee: SEARLE & COPriority: Jan 15, 1993Filed: Jul 1, 2002Published: Jan 16, 2003
Est. expiryJan 15, 2013(expired)· nominal 20-yr term from priority
C07D 333/18C07D 307/38C07D 333/16C07D 333/38C07D 333/28C07D 307/58A61K 31/365C07D 409/04A61K 31/341A61P 17/02
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A class of 3,4-diaryl substituted thiophene, furan and pyrrole derivatives and analogs thereof, pharmaceutical compositions containing them and methods of using them to treat inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: wherein Y is selected from O, S and NR 1 ; wherein R 1 is selected from hydrido and lower alkyl; wherein X is one or two substituent selected from hydrido, halo, lower alkoxycarbonyl and carboxyl; wherein R 2 and R 3 are independently aryl or heteroaryl; and wherein R 2 and R 3 are optionally substituted at a substitutable position with one or more radicals selected from sulfamyl, alkylsulfonyl, halo, lower alkoxy and lower alkyl; or a pharmaceutically-acceptable salt thereof.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound of Formula I  
       
         
           
           
               
               
           
         
       
       wherein Y is selected from S, O, and NR 1 ;  
       wherein R 1  is selected from hydrido and C 1 -C 6  alkyl;  
       wherein X is one or more substituents selected from 
 a) hydrido, halo, cyano, nitro, hydroxy, acyl, lower alkyl substituted at a substitutable position with a substituent selected from halo, hydroxyl, amino, acylamino, lower alkylamino, lower alkyl(acyl)amino, acyl, aryl optionally substituted with hydroxyl, a heterocyclic group, hydroxyimino and lower alkoxyimino, lower alkenyl optionally substituted at a substitutable position with cyano, amino, optionally substituted at a substitutable position with a radical selected from acyl and lower alkylsulfonyl, sulfo, sulfamoyl optionally substituted with a substituent selected from the group consisting of lower alkyl, halo(lower)alkyl, aryl hydroxyl, lower alkylamino(lower)alkyl, a heterocyclic group and (esterified carboxy)lower alkyl, N-containing heterocyclicsulfonyl, a heterocyclic group optionally substituted at a substitutable position with a substituent selected from the group consisting of hydroxyl, oxo, amino and lower alkylamino,  
 b) S(O) n R 5 , wherein R 5  is C 1 -C 6  alkyl optionally substituted at a substitutable position with fluoro, and n is 0, 1 or 2,  
 c) C(R 6 )(OR 8 )(R 7 ) wherein R 6  and R 7  independently are selected from CF 3 , CF 2 H, CFCl 2 , CF 2 Cl, CClFH, CCl 2 F, CF 3 CF 2  and C 1 -C 2  alkyl, and wherein R 8  is selected from hydrido, C 1 -C 4  alkyl, (C 1 -C 3  alkyl)C(O) and CO 2 R 9 , wherein R 9  is C 1 -C 4  alkyl,  
 d) C(O)ZR 4 , wherein Z is O, N, or S, and R4 is selected from hydrido, C 1 -C 6  alkyl and aryl, and when Z is N then R 4  is independently taken twice, and  
 e) C(R 9 )(NHR 11 )(R 10 ), wherein R 9  and R 10  are independently selected from CF 3 , CF 2 H, CFCl 2 , CF 2 Cl, CClFH and CCl 2 H, and R 11  is selected from hydrido and C 1 -C 3  alkyl; and  
 wherein R 2  and R 3  are independently selected from aryl or heteroaryl, wherein the aryl or heteroaryl radical is optionally substituted at a substitutable position with a radical selected from halo, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, nitro, amide, amino, lower alkylamino, sulfamyl and lower alkylsulfonylamino;  
 provided that at least one of R 2  or R 3  is substituted with lower alkylsulfonyl or sulfamyl; p 1  or a pharmaceutically-acceptable salt thereof.  
 
     
     
         2 . A compound of  claim 1  wherein X is S(O) n R 5 , wherein R 5  is C 1 -C 6  alkyl optionally substituted at a substitutable position with fluoro, and n is 0, 1 or 2; or a pharmaceutically-acceptable salt thereof.  
     
     
         3 . A compound of  claim 1  wherein X is C(R 6 )(OR 8 )(R 7 ) wherein R 6  and R 7  independently are selected from CF 3 , CF 2 H, CFCl 2 , CF 2 Cl, CClFH, CCl 2 F, CF 3 CF 2  and C 1 -C 2  alkyl; wherein R 8  is selected from hydrido, C 1 -C 4  alkyl, (C 1 -C 3  alkyl)C(O) and CO 2 R 9 ; and wherein R 9  is C 1 -C 4  alkyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         4 . A compound of  claim 1  wherein X is C(R 9 )(NHR 11 )(R 10 ), wherein R 9  and R 10  are independently selected from CF 3 , CF 2 H, CFCl 2 , CF 2 Cl, CClFH and CCl 2 H, and R 11  is selected from hydrido and C 1 -C 3  alkyl; or a pharmaceutically-acceptable salt thereof.  
     
     
         5 . A compound of  claim 1  wherein R 2  and R 3  are independently selected from aryl and heteroaryl, wherein the aryl or heteroaryl radical is optionally substituted at a substitutable position with halo, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, nitro, amino, lower alkylamino, sulfamyl and lower alkylsulfonylamino; or a pharmaceutically-acceptable thereof, provided that at least one of R 2  or R 3  is substituted with lower alkylsulfonyl or sulfamyl.  
     
     
         6 . Compound of  claim 1  wherein X is one or two substituents selected from hydrido, halo, cyano, nitro, hydroxyl, acyl, lower alkyl substituted at a substitutable position with a substituent selected from halo, hydroxyl, amino, acylamino, lower alkylamino, lower alkyl(acyl)amino, acyl, aryl optionally substituted with hydroxyl, a heterocyclic group, hydroxyimino and lower alkoxyimino, lower alkenyl optionally substituted at a substitutable position with cyano, amino optionally substituted at a substitutable position with a radical selected from acyl and lower alkylsulfonyl, sulfo, sulfamoyl optionally substituted with a substituent selected from the group consisting of lower alkyl, halo(lower)alkyl, aryl, hydroxyl, lower alkylamino(lower)alkyl, a heterocyclic group and (esterified carboxy)lower alkyl, N-containing heterocyclicsulfonyl, a heterocyclic group optionally substituted at a substitutable position with a substituent selected from the group consisting of hydroxyl, oxo, amino and lower alkylamino; and wherein R 2  and R 3  are independently selected from aryl and heteroaryl, wherein the aryl or heteraryl radical is optionally substituted at a substitutable position with a radical selected from halo, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, nitro, amino, amide, lower alkylamino, sulfamyl and lower alkylsulfonylamino; or a pharmaceutically-acceptable salt thereof, provided that at least one of R 2  or R 3  is substituted with lower alkylsulfonyl or sulfamyl.  
     
     
         7 . Compound of  claim 9  wherein Y is S or O; wherein X is one or two substituents selected from hydrido, halo, cyano, nitro, hydroxyl, carboxy, lower alkoxycarbonyl, lower alkyl substituted at a substitutable position with a substituent selected from halo, hydroxyl, amino, acylamino, lower alkylamino, lower alkyl(acyl)amino, lower alkoxycarbonyl, carboxy, a heterocyclic group, hydroxyimino and lower alkoxyimino, lower alkenyl optionally substituted at a substitutable position with cyano, amino optionally substituted at a substitutable position with a radical selected from acyl and lower alkylsulfonyl, sulfo, sulfamoyl optionally substituted with a substituent selected from the group consisting of lower alkyl, halo(lower)alkyl, aryl, hydroxy, lower alkylamino(lower)alkyl, a heterocyclic group and (alkoxycarbonyl)lower alkyl, N-containing heterocyclicsulfonyl, a heterocyclic group optionally substituted at a substitutable position with a substituent selected from the group consisting of hydroxyl, oxo, amino and lower alkylamino; and wherein R 2  and R 3  are independently selected from aryl and heteroaryl, wherein the aryl or heteroaryl radical is optionally substituted at a substitutable position with a radical selected from halo, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, nitro, amino, amide, lower alkylamino, sulfamyl and lower alkylsulfonylamino; or a pharmaceutically-acceptable salt thereof, provided that at least one of R 2  or R 3  is substituted with lower alkylsulfonyl or sulfamyl.  
     
     
         8 . A compound of  claim 10  wherein X is one or two substituents selected from hydrido, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt thereof.  
     
     
         9 . A compound of Formula II  
       
         
           
           
               
               
           
         
         wherein Y is selected from O, S and NR 1 ;  
         wherein R 1  is selected from hydrido and lower alkyl;  
         wherein X 1  and X 2  are independently selected from hydrido, halo, lower alkoxycarbonyl and carboxyl;  
         wherein R 2  is selected from aryl and heteroaryl; wherein R 2  is optionally substituted at a substitutable position with a radical selected from halo, lower alkoxy and lower alkyl; and  
         wherein R 30  is selected from amino and lower alkyl;  
         or a pharmaceutically-acceptable salt thereof.  
       
     
     
         10 . Compound of  claim 9  wherein Y is O or S; 
 wherein R 2  is selected from phenyl, naphthyl, biphenyl, and pyridyl; wherein R 2  is optionally substituted at a substitutable position with a radical selected from halo, lower alkoxy and lower alkyl; and  
 wherein R 30  is selected from amino and C 1 -C 3  alkyl;  
 or a pharmaceutically-acceptable salt thereof.  
 
     
     
         11 . Compound of  claim 10  wherein X 1  and X 2  are independently selected from hydrido, fluoro, chloro, bromo, iodo, methoxycarbonyl, ethoxycarbonyl and carboxyl; 
 wherein R 2  is phenyl or pydridyl; wherein R 2  is optionally substituted at a substitutable position with a radical selected from fluoro, chloro, bromo, iodo, methoxy, ethoxy, methyl and ethyl; and  
 wherein R 30  is amino or methyl;  
 or a pharmaceutically-acceptable salt thereof.  
 
     
     
         12 . Compound of  claim 11  selected from compounds and their pharmaceutically-acceptable salts, of the group consisting of 
 4-(4-methylsulfonylphenyl)-3-(4-fluorophenyl)thiophene;  
 4-(4-methylsulfonylphenyl)-3-(4-fluorophenyl)-2,5-dibromothiophene;  
 4-(4-methylsulfonylphenyl)-3-(4-fluorophenyl)-2-bromothiophene;  
 ethyl[3-(4-methylsulfonylphenyl)-4-(4-fluorophenyl)thien-2-yl]carboxylate;  
 2-ethoxycarbonyl-4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thienyl-5-carboxylic acid;  
 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thienyl-2,5-dicarboxylic acid  
 4-(4-methylsulfonylphenyl)-3-(4-methoxyphenyl)thiophene;  
 4-(4-methylsulfonylphenyl)-3-(4-methoxyphenyl)-2-bromothiophene;  
 3-(4-methylsulfonylphenyl)-4-phenyl-thiophene;  
 3-(4-methylsulfonylphenyl)-4-(4-methylphenyl)thiophene;  
 3-(4-methylsulfonylphenyl)-4-(2-methyl-4-fluorophenyl)thiophene;  
 2-fluoro-5-[3-(4-methylsulfonylphenyl)thien-4-yl]pyridine;  
 4-[4-(4-fluorophenyl)thien-3-yl]benzenesulfonamide;  
 4-[3-(4-fluorophenyl)-2,5-dibromo-thien-4-yl]benzenesulfonamide;  
 4-[3-(4-fluorophenyl)-2-bromo-thien-4-yl]benzenesulfonamide; and  
 3-(4-fluorophenyl)-4-(methylsulfonylphenyl)furan.  
 
     
     
         13 . A pharmaceutical composition comprising a therapeutically-effective amount of an antiinflammatory compound, said compound selected from a compound of  claim 1 , or a pharmaceutically-acceptable salt thereof.  
     
     
         14 . A pharmaceutical composition comprising a therapeutically-effective amount of an antiinflammatory compound, said compound selected from a compound of claim  9 ; or a pharmaceutically-acceptable salt thereof.  
     
     
         15 . A pharmaceutical composition comprising a therapeutically-effective amount of an antiinflammatory compound, said compound selected from a compound of claim  10 ; or a pharmaceutically-acceptable salt thereof.  
     
     
         16 . A pharmaceutically composition comprising a therapeutically-effective amount of an antiinflammatory compound, said compound selected from a compound of claim  11 ; or a pharmaceutically-acceptable salt thereof.  
     
     
         17 . A pharmaceutical composition comprising a therapeutically-effective amount of an antiinflammatory compound, said compound selected from a compound of claim  12 ; or a pharmaceutically-acceptable salt thereof.  
     
     
         18 . The composition of  claim 17  wherein the compound is 4-[4-(4-fluorophenyl)thien-3-yl]benzenesulfonamide; or a pharmaceutically-acceptable salt thereof.  
     
     
         19 . The composition of  claim 17  wherein the compound is 4-[3-(4-fluorophenyl)-2-bromo-thien-4-yl]benzenesulfonamide; or a pharmaceutically-acceptable salt thereof.  
     
     
         20 . Use of a compound of  claim 1  for preparing a medicamtent for treating inflammation or an inflammation-associated disorder.  
     
     
         21 . Use of a compound of  claim 9  for preparing a medicament for treating inflammation or an inflammation-associated disorder.  
     
     
         22 . Use of a compound of  claim 10  for preparing a medicament for treating inflammation or an inflammation-associated disorder.  
     
     
         23 . Use of a compound of  claim 11  for preparing a medicament for treating inflammation or an inflammation-associated disorder.  
     
     
         24 . Use of a compound of  claim 12  for preparing a medicament for treating inflammation or an inflammation-associated disorder.  
     
     
         25 . Use according to  claim 24  wherein the compound is 4-[4-(4-fluorophenyl)thien-3-yl]benzenesulfonamide; or a pharmaceutically-acceptable salt thereof.  
     
     
         26 . Use according to  claim 24  wherein the compound is 4-[3-(4-fluorophenyl)-2-bromo-thien-4-yl]benzenesulfonamide; or a pharmaceutically-acceptable salt thereof.  
     
     
         27 . Use according to  claim 20  for treating inflammation.  
     
     
         28 . Use according to  claim 20  for treatment of an inflammation-associated disorder.  
     
     
         29 . Use according to  claim 28  wherein the inflammation-associated disorder is arthritis.  
     
     
         30 . Use according to  claim 28  wherein the inflammation-associated disorder is pain.  
     
     
         31 . Use according to  claim 27  wherein the inflammation-associated disorder is fever.

Join the waitlist — get patent alerts

Track US2003013744A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.